-- 奥本海默表示，Viking Therapeutics (VKTX) 在其肥胖症治疗项目中更加注重维持剂量，新增的维持治疗组预计将进一步优化 VK2735 的长期给药方案。 该公司新增了四个皮下注射维持治疗组，使维持治疗组总数达到八个，这些治疗组预计将为 Vanquish 扩展研究和正在进行的维持治疗评估的给药方案提供依据。 奥本海默在周三的一份报告中表示，预计将于 2026 年第三季度获得皮下注射维持治疗项目的数据，如果体重减轻幅度保持不变，则被视为积极结果。该券商表示，Viking Therapeutics 的维持治疗方案与竞争对手不同，并与其健康老龄化理念相符。 该投资公司还表示，新任首席商务官 Neil Aubuchon 的见解正在帮助完善 VK2735 的开发战略和整体产品定位。 奥本海默维持对该股的“跑赢大盘”评级，目标价为 100 美元。 维京公司股价周四下跌4.1%。
Price: $30.02, Change: $-1.31, Percent Change: -4.18%
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%